Integra LifeSciences Holdings Corporation reported its financial results for the fourth quarter and full year ended December 31, 2024. For Q4 2024, total revenues were $442.6 million, an increase of 11.5% on a reported basis and 3.5% organically compared to the prior year. The company achieved GAAP net income of $19.4 million, or $0.25 per diluted share, and adjusted net income of $73.3 million, or $0.97 per diluted share.
For the full year 2024, total reported revenues reached $1,610.5 million, a 4.5% increase from the prior year, though organic sales were down 1.3%. The full-year GAAP net loss was $(6.9) million, or $(0.09) per diluted share, while adjusted net income was $196.9 million, or $2.56 per diluted share. These results were influenced by the Acclarent acquisition and production constraints on Integra Skin.
Looking ahead to 2025, Integra LifeSciences provided full-year revenue guidance in the range of $1,650 million to $1,715 million, representing reported growth of 2.4% to 6.5% and organic growth of 1.0% to 5.0%. Adjusted earnings per diluted share are expected to be between $2.41 and $2.51. For the first quarter of 2025, the company anticipates revenues between $375 million and $385 million, with adjusted EPS in the range of $0.40 to $0.45, reflecting ongoing Compliance Master Plan implementation and currency impacts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.